Insider Monkey on MSN1h
Novo Nordisk A/S (NVO): A High Growth Mega Cap Stock You Can Buy and Hold for the Next 5 Years
We recently compiled a list of the 20 High Growth Mega Cap Stocks You Can Buy And Hold For Next 5 Years. In this article, we ...
Here is Why Novo Nordisk A/S (NVO) is Among the Most Oversold Pharma Stocks to Buy According to Analysts
We recently published a list of the 10 Oversold Pharma Stocks to Buy According to Analysts. In this article, we are going to take a look at where Novo Nordisk A/S (NYSE: NVO) stands against the other ...
FiercePharma4d
Fierce Pharma Asia—Novo Nordisk's fraud accusation; AstraZeneca's China deal; Ono's FDA nod
Ono Pharmaceutical's $2.4 billion Deciphera acquisition has borne fruit. And more. 1. Novo Nordisk to sue KBP Biosciences over alleged fraudulent claims on kidney disease drug Novo Nordisk is ...
Novo Nordisk’s stock is rallying as Hims & Hers’ stock falters. An Ozempic alternative won’t be available for long.
Novo Nordisk shares rallied on Tuesday as a maker of a weight-loss drug alternative confirmed it won’t be selling it for much longer.
Wall Street Journal3d
FDA Declares Shortage of Novo Nordisk’s Wegovy, Ozempic Over
The FDA announcement confirms that the U.S. supply of both prescription-only drugs now meets or exceeds the current and projected demand in the country, Danish pharmaceutical company Novo Nordisk ...
Express & Star8d
Novo Nordisk reprimanded for allegedly failing to disclose payments
Novo Nordisk breached clauses under the Association of the British Pharmaceutical Industry (ABPI) code of practice, according to the Prescription Medicines Code Of Practice Authority (PMCPA).
Novo Nordisk A/S (NVO): Among the Cheap Pharmaceutical Stocks to Buy According to Analysts
We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Analysts. In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against the ...
Reuters20d
Novo Nordisk defends next-gen obesity drug CagriSema, details new trial
LONDON/COPENHAGEN, Feb 5 (Reuters) - Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data published in December that disappointed ...
The Motley Fool23d
Forget Wegovy: Novo Nordisk May Have a New Billion-Dollar Weight Loss Drug On Its Hands
Dual agonists are proving to be especially promising candidates, and many pharmaceutical companies have created some versions. Novo Nordisk recently reported data from a phase 1b/2a clinical trial ...
FiercePharma20d
Novo Nordisk predicts milder growth in 2025 after obesity star Wegovy doubles sales in Q4
With sales of Novo Nordisk’s obesity blockbuster Wegovy ... Nevertheless, the Danish pharma continues to recognize the importance of its production network, with the company noting in its ...
Reuters29d
Novo Nordisk to cap insulin prices in Minnesota settlement; joins Lilly, Sanofi
Patients to pay no more than $35 a month Eli Lilly, Sanofi previously settled overcharging claims Novo Nordisk denies wrongdoing, pledges affordable insulin Jan 27 (Reuters) - Novo Nordisk (NOVOb ...